RU2016123169A - Твердые композиции триглицеридов и их применение - Google Patents

Твердые композиции триглицеридов и их применение Download PDF

Info

Publication number
RU2016123169A
RU2016123169A RU2016123169A RU2016123169A RU2016123169A RU 2016123169 A RU2016123169 A RU 2016123169A RU 2016123169 A RU2016123169 A RU 2016123169A RU 2016123169 A RU2016123169 A RU 2016123169A RU 2016123169 A RU2016123169 A RU 2016123169A
Authority
RU
Russia
Prior art keywords
less
composition according
poly
solid composition
solid
Prior art date
Application number
RU2016123169A
Other languages
English (en)
Russian (ru)
Inventor
Джон КЛОПП
Габриелл МОРРИС
Эмиль КАККИС
Стивен ДЖАНГЛЗ
Original Assignee
Ультраджиникс Фармасьютикал Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53058066&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2016123169(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ультраджиникс Фармасьютикал Инк. filed Critical Ультраджиникс Фармасьютикал Инк.
Publication of RU2016123169A publication Critical patent/RU2016123169A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fats And Perfumes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
RU2016123169A 2013-11-14 2014-11-14 Твердые композиции триглицеридов и их применение RU2016123169A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361904369P 2013-11-14 2013-11-14
US61/904,369 2013-11-14
PCT/US2014/065693 WO2015073816A1 (en) 2013-11-14 2014-11-14 Solid compositions of triglycerides and uses thereof

Publications (1)

Publication Number Publication Date
RU2016123169A true RU2016123169A (ru) 2017-12-19

Family

ID=53058066

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016123169A RU2016123169A (ru) 2013-11-14 2014-11-14 Твердые композиции триглицеридов и их применение

Country Status (18)

Country Link
US (6) US20160243071A1 (enExample)
EP (3) EP3068383B1 (enExample)
JP (4) JP2017501972A (enExample)
KR (1) KR102291310B1 (enExample)
CN (2) CN113181158A (enExample)
AR (2) AR099353A1 (enExample)
AU (1) AU2014348470B2 (enExample)
CA (2) CA2929688C (enExample)
CL (1) CL2016001130A1 (enExample)
ES (1) ES2833294T3 (enExample)
IL (1) IL245588B (enExample)
MX (2) MX383005B (enExample)
MY (1) MY177028A (enExample)
PE (1) PE20161024A1 (enExample)
PH (1) PH12016500821A1 (enExample)
RU (1) RU2016123169A (enExample)
TW (1) TWI640327B (enExample)
WO (1) WO2015073816A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017501972A (ja) 2013-11-14 2017-01-19 ウルトラジェニクス ファーマシューティカル インク．Ｕｌｔｒａｇｅｎｙｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｉｎｃ． トリグリセリドの固体組成物及びその使用
US20190076383A1 (en) * 2017-09-08 2019-03-14 Horizon Therapeutics, Llc Methods for treating urea cycle disorders
US12419852B2 (en) 2018-08-27 2025-09-23 Exerkine Corporation Method for treating lysosomal storage disease
US11583542B2 (en) * 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
CN113476408A (zh) * 2021-07-23 2021-10-08 兆科药业（广州）有限公司 一种苯丁酸甘油酯颗粒剂及其制备方法与应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3337596A (en) 1965-02-18 1967-08-22 Procter & Gamble Synthesis of mixed glycerides
JPS5215834A (en) 1975-07-12 1977-02-05 Ajinomoto Kk Method of producing food composition
US4753963A (en) 1985-09-26 1988-06-28 The Procter & Gamble Company Nutritional fat suitable for enteral and parenteral products
JPH07102106B2 (ja) 1987-06-10 1995-11-08 日清製粉株式会社 経口，経管栄養食の製造法
KR100318295B1 (ko) 1989-07-05 2002-11-16 가부시키가이샤 저펜에너지 냉각윤활제
EP0421581A1 (en) 1989-10-03 1991-04-10 Warner-Lambert Company Chewable spray dried spheroidal microcapsules and wax coated microcapsules and methods for preparing same
JPH0692848A (ja) 1992-09-11 1994-04-05 Sagami Chem Res Center 糖尿病治療用乳剤
JPH06145688A (ja) 1992-11-10 1994-05-27 Nippon San Sekiyu Kk 冷凍機用潤滑油組成物
JP2800610B2 (ja) * 1992-12-15 1998-09-21 不二製油株式会社 水中油型乳化物の製造法
JP3522843B2 (ja) * 1994-07-29 2004-04-26 昭和産業株式会社 リポ製剤
US5746933A (en) 1994-11-07 1998-05-05 Nippon Oil Co., Ltd. Lubricating oil and composition for refrigerating machine, and refrigerating machine
WO1996024571A1 (en) 1995-02-07 1996-08-15 Brusilow Saul W Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders
US5698210A (en) 1995-03-17 1997-12-16 Lee County Mosquito Control District Controlled delivery compositions and processes for treating organisms in a column of water or on land
JPH08311480A (ja) * 1995-05-18 1996-11-26 D H Ee Kodo Seisei Chushutsu Gijutsu Kenkyu Kumiai 高純度トリアシルグリセロールからなる油脂の製造方法及び高度不飽和脂肪酸含有油脂組成物
JP3391798B2 (ja) 1995-09-25 2003-03-31 花王株式会社 エステル化合物及び潤滑油組成物
US5908631A (en) * 1997-02-27 1999-06-01 L'oreal S.A. Monohydric alcohol-free composition for topical use comprising solubilized ethylcellulose
US5885616A (en) 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
US6278006B1 (en) 1999-01-19 2001-08-21 Cargill, Incorporated Transesterified oils
US20030162833A1 (en) 2001-08-01 2003-08-28 Roe Charles R. Fatty acid treatment for cardiac patients
CA2361070C (en) 1999-02-05 2012-04-17 Baylor Research Institute Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid
DE60130083T2 (de) 2000-10-16 2008-05-15 Nof Corp. Herstellung von Estern für die Verwendung als Basisschmieröl
JP4282289B2 (ja) 2002-08-29 2009-06-17 株式会社ジャパンエナジー 流体軸受用潤滑油及びそれを用いた流体軸受
AU2003261928A1 (en) 2002-09-05 2004-03-29 The Nisshin Oillio Group, Ltd. Agents, foods and drinks controlling lipid metabolism
EP1628622A4 (en) * 2003-05-20 2008-12-17 Baylor Res Inst FIVE AND FIFTH CARBON FATTY ACIDS FOR THE TREATMENT OF METABOLISM DISORDERS AND AS FOOD SUPPLEMENTS
US20050058673A1 (en) 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
WO2005120484A1 (ja) 2004-06-09 2005-12-22 Kurume University グレリンの生理学的機能のレギュレーター
US7141114B2 (en) * 2004-06-30 2006-11-28 Rec Silicon Inc Process for producing a crystalline silicon ingot
CA2573054C (en) 2004-07-02 2012-10-09 Baylor Research Institute Glycogen or polysaccharide storage disease treatment method
MX2007010908A (es) * 2005-03-10 2007-12-05 3M Innovative Properties Co Composiciones antimicrobianas que comprenden esteres de acidos hidroxicarboxilicos.
TW200719884A (en) 2005-03-10 2007-06-01 3M Innovative Properties Co Methods of treating ear infections
FR2894822B1 (fr) 2005-12-20 2011-11-18 Pf Medicament Composition pharmaceutique contenant des acides gras omega-3
US20090017118A1 (en) 2006-02-10 2009-01-15 Sportscom Danmark Aps Coated tablets, their methods of preparation, and related uses
JP5099808B2 (ja) 2006-05-29 2012-12-19 独立行政法人農業・食品産業技術総合研究機構 脂質代謝改善用組成物
WO2008099025A2 (en) 2007-05-08 2008-08-21 Dsm Ip Assets B.V. Body-weight maintenance and body composition
JP5296366B2 (ja) * 2007-10-29 2013-09-25 日清オイリオグループ株式会社 医薬品用持久力向上剤および持久力向上用医薬品
CN103550214A (zh) 2008-03-26 2014-02-05 塔罗制药北美有限公司 用于口服药剂的稳定脂质组合物
WO2009134460A1 (en) 2008-04-29 2009-11-05 Hyperion Therapeutics Methods of treatment using ammonia-scavenging drugs
JP5577341B2 (ja) 2008-08-29 2014-08-20 ハイペリオン セラピューティクス， インコーポレイテッド アンモニア捕捉薬を使用する処置方法
KR20120129898A (ko) 2009-12-30 2012-11-28 베일러 리서치 인스티튜트 알츠하이머 질환 및 노화 뇌를 위한 보충대사 치료요법
MX2012014520A (es) 2010-06-14 2013-03-05 Baylor Res Inst Dieta de triheptanoina para tratamiento de enfermedad del cuerpo de poliglucosano (apbd).
US8932646B2 (en) 2010-06-18 2015-01-13 Bausch & Lomb Incorporated Peroxide contact lens care solution
CN101919453B (zh) * 2010-08-16 2013-04-10 苏州市佳禾食品工业有限公司 中碳链脂肪酸粉末油脂及其制备方法
JP5820256B2 (ja) 2011-02-10 2015-11-24 株式会社ファンケル 自己乳化製剤
WO2013012699A2 (en) 2011-07-15 2013-01-24 3M Innovative Properties Company Polyurethane based coating compositions
EP3263102A1 (en) 2011-09-30 2018-01-03 Horizon Therapeutics, LLC Methods of therapeutic monitoring of nitrogen scavenging drugs
JP6080269B2 (ja) 2012-02-15 2017-02-15 日清オイリオグループ株式会社 飼料用組成物、飼料、及び飼料の製造方法
TWI572352B (zh) 2012-03-01 2017-03-01 波麥堤克藥學Ｓｍｔ有限公司 用於製備具中鏈長度之脂肪酸的三酸甘油酯之方法
WO2013158616A1 (en) * 2012-04-16 2013-10-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Treatment of medium-chain acyl-coa dehydrogenase deficiency
AU2013358951C1 (en) 2012-12-13 2019-06-27 Baylor Research Institute Triheptanoin for the treatment of glucose transporter 1 deficiency
EP3027180B1 (en) 2013-07-31 2021-07-07 The Children's Hospital of Philadelphia Compositions and methods of the treatment of fatty acid metabolism disorders
JP2017501972A (ja) 2013-11-14 2017-01-19 ウルトラジェニクス ファーマシューティカル インク．Ｕｌｔｒａｇｅｎｙｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｉｎｃ． トリグリセリドの固体組成物及びその使用
US11844775B2 (en) 2018-07-11 2023-12-19 University of Pittsburgh—of the Commonwealth System of Higher Education Method of treating fatty acid oxidation disorders using Omega3/Omega6 unsaturated or branched chain fatty acids

Also Published As

Publication number Publication date
AR099353A1 (es) 2016-07-20
IL245588B (en) 2021-08-31
TWI640327B (zh) 2018-11-11
CA2929688A1 (en) 2015-05-21
ES2833294T3 (es) 2021-06-14
US20250120935A1 (en) 2025-04-17
CA3197154A1 (en) 2015-05-21
JP2024129109A (ja) 2024-09-26
US12551461B2 (en) 2026-02-17
CN113181158A (zh) 2021-07-30
EP3782610A1 (en) 2021-02-24
KR102291310B1 (ko) 2021-08-23
CN105764497A (zh) 2016-07-13
EP3068383B1 (en) 2020-09-16
TW201609189A (zh) 2016-03-16
US20200069631A1 (en) 2020-03-05
MX2016006329A (es) 2016-09-06
CL2016001130A1 (es) 2017-01-20
US20250120936A1 (en) 2025-04-17
JP2022107017A (ja) 2022-07-20
MX2021001790A (es) 2021-04-19
AU2014348470B2 (en) 2020-01-30
JP2017501972A (ja) 2017-01-19
PE20161024A1 (es) 2016-11-10
AR130666A2 (es) 2025-01-08
CA2929688C (en) 2023-06-13
AU2014348470A1 (en) 2016-05-26
EP4789718A2 (en) 2026-08-12
US20230181513A1 (en) 2023-06-15
MX383005B (es) 2025-03-13
MY177028A (en) 2020-09-02
EP3068383A4 (en) 2017-11-08
JP2020111585A (ja) 2020-07-27
KR20160084407A (ko) 2016-07-13
IL245588A0 (en) 2016-06-30
WO2015073816A1 (en) 2015-05-21
US20160243071A1 (en) 2016-08-25
US20250120934A1 (en) 2025-04-17
PH12016500821A1 (en) 2016-06-13
EP3068383A1 (en) 2016-09-21

Similar Documents

Publication Publication Date Title
KR101413339B1 (ko) 폴리불포화 지방산의 알킬 에스테르에 현탁된 스타틴의마이크로캡슐을 포함하는 약학 조성물
TWI571271B (zh) 包含ω－３脂肪酸酯及ＨＭＧ－ＣｏＡ還原酶抑制劑之口服複合組成物
RU2006115596A (ru) Твердые дозированные формы, включающие фибрат и статин
RU2612022C2 (ru) Фармацевтические композиции
FR2698560A1 (fr) Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications.
CN121220615A (zh) 贮存稳定的配制物
CN105848644A (zh) 经口药物组合物
CA2799407A1 (fr) Forme pharmaceutique orale alcoolo-resistante
JP2017501972A5 (enExample)
JP2016501248A5 (enExample)
JP2020111585A (ja) トリグリセリドの固体組成物及びその使用
US20230148650A1 (en) Novel coating composition and coated compositions comprising the same
JP6148510B2 (ja) ソホロリピッド含有粉末組成物
WO2012014052A4 (en) Novel coated extended release pharmaceutical compositions containing paliperidone
US9200164B2 (en) Coating system
JP2022000013A (ja) 新規コーティング系（ｉｉ）
KR20220119374A (ko) 결정질 형태의 코팅 매트릭스로 위보호된 과립형 박테리아, 이의 제조 방법 및 이의 조성물
HK40056892A (en) Solid compositions of triglycerides and uses thereof
WO2023120558A1 (ja) 還元型補酵素ｑ１０の保存方法
WO2021023850A1 (en) Method of preparing a solid dosage form and a binder
CA2943021A1 (en) Solid formulations containing omega-3 and resveratrol